Ranbaxy Laboratories has hired the consulting group of the former mayor of New York, Rudolph Giuliani, the day after the US Food and Drug Administration blocked the importation of more than 30 of the Indian firm’s drugs.

Ranbaxy says it has retained the services of Giuliani Partners for advice and a review of compliance issues related to the agency's move. The FDA issued an ‘import alert’ to detain at the US border any drugs made at Ranbaxy’s Dewas and Paonta Sahib facilities because of “ongoing procedural violations in manufacturing”.

This is the second warning that Ranbaxy has received in the past two years and the Indian had earlier expressed surprise at the import alert, saying “the company has responded to each concern FDA has raised during the past two years and had thought that progress was being made”. Now Ranbaxy, in announcing the Giuliani link-up, is saying that it is “committed to a swift resolution to address these issues and to continuing to supply the global marketplace with safe and effective pharmaceuticals".

The news that the FDA has banned the 30 drugs led to a 10% decline in Ranbaxy’s shares. Also analysts at JPMorgan issued a research note saying that the import alert “possibly means loss of sales for Ranbaxy in the North American market and, more importantly, given the string of exclusivity launches in the USA, we believe this is clearly negative”.

However, the problems with the FDA are unlikely to stall Daiichi Sankyo’s bid to buy a controlling stake in Ranbaxy. The Japanese firm says it is proceeding with the deal as planned and while aware of the FDA's warning letter, it is not in a position to comment.